This market research study determines the increase in changes and the aspects which are likely to have an impact on the growth of the 2025 market. Increased demand for the technologies is also one of the factors, which are likely to boost the growth of this industry. The market research study uses several tools and techniques which are used for the determination of the growth of the 2025 market.
The global autoimmune disease therapeutics market accounted for nearly $109.83 billion in 2017, and is expected to reach $153.32 billion by 2025, growing at a CAGR of 4.2% from 2018 to 2025.
Growth Drivers and Industry Trends
Rise in the adoption of autoimmune disease therapeutics, increase in incidence of autoimmune disease, and wide availability of advanced therapeutics are the major drivers of the global autoimmune disease therapeutics market. However, high cost associated with advanced autoimmune disease therapeutics hampers the market. On the contrary, growth opportunities in the emerging economies and strong presence of pipeline drugs are expected to create lucrative opportunities in the near future.
Rheumatic disease segment to maintain its dominant share by 2025
Based on indication, rheumatic disease segment contributed nearly half of the total market share in 2017 and will maintain its dominant share by 2025. Moreover, this segment would register the highest growth rate, with a CAGR of 5.2% from 2018 to 2025. This is due to increase in prevalence, surge in R&D activities, and availability of advanced therapeutics. The report also analyzes type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and others.
Leading market players
Leading market players analyzed in the research include Abbott Laboratories, Amgen Inc., AbbVie Inc.,
Bristol-Myers Squibb Company, AstraZeneca plc., Johnson & Johnson, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, and UCB S.A.
Read More: https://www.alliedmarketresearch.com/autoimmune-disease-therapeutics-market
0 Comments